Introduction
Bacteria, viruses and cells contain biocomplexes and nanomachines composed of multiple subunits, such as biomotors [1, 2, 3, 4] , pumps [5] , exosomes [6, 7, 8] , valves [9, 10, 11] , membrane pores [12, 13, 14, 15] , chaperonins [16] , PCNA [17] , ATPase [18, 19] , and tubes [20] . From a nanobiotechnological standpoint, these nanomachines can be used and converted to build sophisticated nano-devices including molecular sensors [21, 22, 23] , patterned arrays, tuators [24] , chips, microelectromechanical systems (MEMS) [25] , molecular sorters [26] , single pore DNA sequencing apparatus [12, 13, 21, 27] or other revolutionary electronic and optical devices [28, 29] . From a pharmaceutical standpoint, these multi-subunit biocomplexes or nanomachines have a potential for use as drug targets for therapeutics, as well as diagnostic applications such as pathogen detection, disease diagnosis, drug delivery, and treatment of diseases [22, 23, 30, 31] . In the ASCE (Additional Strand Catalytic E) family including the AAA+ (ATPases Associated with diverse cellular Activities) and the FtsK-HerA superfamily in bacteria, viruses and cells, there are nanomotors that perform a wide range of functions [19, 32, 33] critical to chromosome segregation, bacterial binary fission, DNA/RNA and cell component transportation, membrane sorting, cellular reorganization, cell division, RNA transcription, as well as DNA replication, riding, repair, and recombination [1, 34, 35, 36] . One of the directions of NIH Roadmap is to utilize these cellular nanomachines and biocomplexes for biomedical applications. Nanomedicine(Lond.) (2015) 10(12), 1881-1897 ISSN 1743-5889
The approach of developing highly potent drugs through targeting of protein or RNA complexes with high stoichiometry has never been reported due to challenges in comparing efficacies of two drugs that can be confused by target essentiality with binding affinity. For instance, if two drugs target two stoichiometrically different targets, it becomes extremely difficult to prove whether the difference in drug efficiency is due to differences in their target binding affinity or essential level in the growth of the biological organism. In order to quantify effects from targeting biocomplexes of different stoichiometry, a well-studied multi-component system is required that allows empirical comparison of functional inhibition of individual components that are composed of different number of subunits.
An example of one nanobiomachine is the dsDNA translocation motor, for which the ATPase protein is a pivotal component that assembles into a hexameric ring structure and translates the action of ATP binding and hydrolysis into mechanical motion to translocate DNA physically. The DNA packaging motor of bacteriophage phi29 (Fig. 1A) [9, 51, 52, 53] is composed of three essential co-axial rings:
1) a dodecameric connector ring located at the vertex of the viral procapsid; 2) a hexameric packaging RNA (pRNA) ring [52] bound to the N-terminus of the connector [54] , and 3) a hexameric ring of ATPase gp16 attached to the helical region of pRNA [10, 19, 55] , powered through the hydrolysis of ATP resulting in DNA packaging. The use of Yang Hui's Triangle (Fig. 1B) or binomial distribution to determine the stoichiometry of the pRNA was first reported in 1997 [56] . The use of similar mathematical methods to determine the stoichiometry of the protein subunits has also been reported more recently [51] . The copy number of ATP molecules required to package one full phi29 genomic dsDNA was predicted to be 10000 [57] . It has recently been shown that this hexameric motor uses a revolution mechanism without rotation to translocate its genomic DNA [10, 19, 33, 35, 36, 58, 59] .
In this report, we hypothesize that the inhibitory efficiency of a drug is related to the stoichiometry of its targeted biocomplex; the higher the stoichiometry of the target complex, the more efficient the drug. This can lead to the development of potent therapeutics against highstoichiometric biomachines or biocomplexes as drug targets. We 
Materials and Methods

Preparation of mutant genomic dsDNA
Phi29 genomic DNA-gp3 was purified from B. subtilis SpoA12 cells by CsCl gradient ultracentrifugation as described previously [63] . Mutant dsDNA was prepared by digesting the phi29 genomic dsDNA with EcoR1 restriction enzyme in fast digest buffer (Fermentas) at 37 °C for 1 hour followed by ethanol precipitation. The mutant DNA was tested by 1% agarose gel electrophoresis, stained by ethidium bromide (Sigma) and imaged by Typhoon (GE).
Preparation of mutant pRNA
Wild-type phi29 pRNA and inactive mutant as drugged pRNA were prepared by in vitro transcription. In the inactive mutant pRNA, the first four bases "UUCA" located at the 5' end were mutated to "GGGG". BglII digested plasmid pRT71 was used as DNA template [64] in the PCR reaction for both RNAs. Oligonucleotide 5'-TAA TAC GAC TCA CTA TAG GGG TGG TAC-3' and 5'-TTA TCA AAG TAG CGT GCA C-3' were used as primers for mutant pRNA. RNAs were then transcribed by T7 RNA polymerase using double-stranded DNA generated from PCR, as described before [65] . The RNA from in vitro transcription was further purified by 8 M urea 8% polyacrylamide gel electrophoresis as described previously [64] .
Preparation of mutant ATPase gp16
The purification of wild-type gp16 has been described previously [63] . The walker B mutant gp16 was constructed by introducing mutations in the gp16 gene. The amino acid residues D255 and E256 in walker B motif of gp16 were mutated to E255 and D256, respectively. The mutation was introduced with the Stratagene Quick Change site-directed mutagenesis kit using appropriate primers. The expression and purification of protein were carried out followed a published procedure [51] .
Antisense oligonucleotides
Antisense oligonucleotides P3 and P15 were designed to be reversely complementary to different regions on the pRNA molecule and chemically synthesized by IDT. P3 oligo (5'-TTGCCATGATTGACAAC-3') targets the region of 83-99 nucleotides at the 3'end of pRNA, P15 oligo (5'-AAGTACCGTACCATTGA-3') targets the region of 1-17 nucleotides at the 5'end of pRNA. P8 oligo (5'-TAATACGACTCACTATAGGGGTGGTAC-3') was designed as a non-targeting control in the test. 1 μl of individual oligos at 100 μM were mixed with 1 μl of pRNA at 4 μM and dialyzed on a 0.025 μm mixed cellulose esters VSWP filter membrane (Millipore Corp) against TBE buffer (89 mM Tris-HCl, pH 8.3, 89 mM boric acid, 2.5 mM EDTA) at room temperature for 15 min. The purified RNA complex was used for in vitro phi29 assembly assay.
In vitro phi29 assembly assay
Purified components were subjected to in vitro viral assembly assay as described previously [66] . Briefly, 10 μg of purified procapsids were mixed with 100 ng of pRNA in 5 μl of reaction buffer (10 mM ATP, 6 mM 2-mercaptoethanol, and 3 mM spermidine in TMS buffer) at room temperature for 30 min. Purified DNA-gp3 and gp16 were then added and the reaction mixture was incubated at room temperature for one hour to initiate DNA packaging. Finally, the DNA filled procapsids were incubated with 10 μl of gp8.5-9 extract from E.coli containing plasmid pARgp8.5-9 and 20 μl of gp11-14 extract from E.coli to complete the infectious phage assembly.
The newly assembled infectious viruses were plated with inoculated B. subtilis bacteria Su +44 cells onto a half LB plate covered with top agar. After 12 hour incubation at 37 °C, the viral assembly efficiency (plaque-forming unit, PFU) was calculated by counting the formed plaque numbers. Mixing different ratios of mutant with wild-type components, while keeping all other components the same, the viral assembly efficiency (PFU) versus ratio of mutant components gave an empirical curve for vial assembly inhibition assay, and it was compared with theoretical curves from the binomial distribution equation.
In vivo viral assembly assay
Plasmid pRBwtRNA containing the pRNA coding sequence under T7 promoter was constructed by ligating the fragment coding pRNA sequence and T7 promoter into pRB381-L550 vector (modified and kindly provided by M. Wang and H. Zalkin) following a previously described method [67] . Plasmid pRBmutRNA contained mutant pRNA under its natural promoter PE1 sequence, and the mutation was changing sequence 5'UUGA-3' at its 3'end to 5'GGGG-3'. The DNA fragments coding mutant pRNA sequence and PE1 sequence were prepared by PCR as described previously [67] ; and digested with HindIII-BglII restriction enzyme. The mutant pRNA sequence coding fragment was further ligated with a 6.0kb fragment from pRB381-L550 that was digested with HindIII and partially digested with BglII.
The plasmids pRBmutRNA, pRBwtRNA, and pRB381-L550 were transformed into B. subtilis cells following methods described previously [67] . The B. subtilis cells harboring transformed plasmids were incubated in 416 medium with 10 mg/ml of neomycin for 3 hours at 37 °C and then plated onto LB-neomycin (10 mg/ml) plates for plaque formation analysis.
Results
The Definition of "Stoichiometry"
The definition of the stoichiometry in this report is different from conventional definition of stoichiometry used to evaluate drug efficiency. Conventionally the concept of stoichiometry refers to the number of a drug binding to each target molecule, which is also known as B max . In this study the definition of stoichiometry refers to Nanomedicine(Lond.) (2015) 10(12), 1881-1897 ISSN 1743-5889 the copy number of subunit within a biocomplex or the nanomachine that serves as drug target.
The definition of "K value", and K = 1 is one key for ultra-high inhibition efficacy
Suppose a biocomplex drug target contains Z copies of subunits, then K is the copy number (K ≤ ) of drugged subunits required to inhibit the function of the complex or the nanomachine. As an analogy to the difference between the parallel circuit and the serial circuit, when the Christmas lights are arranged in a parallel circuit, any light bulbs that are burnt out will not affect other bulbs. But in a serial circuit, any one light bulb that is broken will stop the entire lighting system, which is K=1. Thus, the K value is the key to the probability of inactive nanomachines or biocomplexes by combination and permutation of all subunits. K equals 1 is critical for such ultra-high inhibition effect. The foundation of the approach in this report is the difference in probability of inhibited biocomplexes in systems of different K values with combination and permutation algorithms. Biological systems display complicated reactions. Many reactions involve multiple subunits to work cooperatively sequentially or processively to accomplish one essential biological function [33, 68, 69, 70, 71, 72, 73, 74, 75] . Single assembly pathways have been reported in the viral assembly system [76, 77] . In most cases of the sequential, cooperative, and precessive action, inactivation of any one, not necessary all, of the subunits will result in inhibition of its function, thus K =1. Drug synergism was utilized in multi-target drug therapy; in short, a drug combination can simultaneously act on multiple targets in disease networks to produce a synergistic effect [50, 78] . However, our design reported here is unique from the conventional synergistic approach. We suggest that using multisubunit biocomplexes as drug target could lead to development of ultra-high potent drugs. In a conventional six-component system, for example one drug is designed to target component #3 to stop the entire system, since the drug can only target component #3, the condition fits the model of Z=1 and K=1. Thus, the inhibition efficiency and substrate targeting efficiency (p) of drug will be in linear relationship. However, in the system in this report, the entire system will be blocked when drug targets any subunit of a hexamer, which is Z=6 and K=1. Thus the probability of remaining undrugged targets will be q 6 , where q represents the fraction of untargeted hexamer subunits; in other words, the drug inhibition efficiency will be 1-q 6 , which increases following a power function compared to the linear for conventional mono-subunit approaches.
Assuming that at least K copies of drugged subunits were needed to deactivate the nanomachine or biocomplex, the probability of functional biocomplexes in the presence of various ratios of inhibited and wild-type subunits could be predicted from equation 2. When K=1, it implies that drug binding to one subunit will inactivate the subunit, and one drugged subunit per multi-subunit complex is sufficient to inhibit the overall function of the complex. The inhibition efficiency by drugs targeting multi-subunit biocomplexes with stoichiometry of Z will equal , as shown in table 1. An example for such a probability calculation when Z = 6 and K = 1 is as follows: since it was assumed that 6 (Z = 6) copies of subunits per element were required for function and one drugged subunit (K = 1) was sufficient to block its activity, all elements possessing 1 to 5 copies of drugged subunits would be non-functional (Fig. 1C ). Only those complexes possessing 6 copies of normal subunits will be functional. The chance for a complex containing 6 copies of unaffected subunits in a population is q 6 and the inhibition efficiency will be .
Rationale behind selection of multi-subunit biocomplexes as efficient drug targets
Mechanisms for drug inhibition of organism growth are to block or stop an essential biological element from functioning. When a drug is designed to target the subunit of a complex with targeting efficiency p, a fraction of subunits will not interact with the drug (a percentile given as q, p+q=1) and will remain active and exert their function properly. Some biological elements are monomers containing only one subunit, while other biological elements, such as the bio-motors of hexameric AAA+ family, consist of multiple-subunits [19, 34] . Conventional drugs are designed to inhibit pathogenesis through targeting of a single subunit molecule, such as an enzyme or a structural protein of a virus. In this situation, the inhibition efficiency is proportional to the substrate targeting efficiency p and the effect is proportional to the first order of p. As described above, in most cases of sequential action or cooperatives in multiple subunit complexes, inactivation of one, not all, of the subunits will result in inhibition of its function. Thus, if complexes containing Z copies of subunits exercise their function in a sequential and cooperative way, then K=1, and the fraction of the uninhibited active biocomplex will be q z , a higher order with regards to the stoichiometry. The inhibition proportion will equal In this investigation, a well-defined in vitro phi29 viral assembly system was used to represent a multi-subunit nano-machine target, with the mutant component representing a target component that have been inactivated by an effective drug. Then, the inhibition efficiencies by targeting different elements of the phi29 DNA packaging motor with different stoichiometry were compared. The viral assembly competition assays combined with binomial distribution analysis illustrated the concept that drug targeting functional biological complexes of a higher-stoichiometry has a higher efficiency than drug acting on a single subunit target.
When the target element is a monomer containing only one subunit, the inhibition efficiency can be calculated through a binomial distribution (equation 1), where p and q are the fractions of drugged (substrate targeting efficiency) and undrugged (normal active elements) subunits, respectively (p + q = 1).
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However, when the target element contains multiple subunits, a high order binomial distribution (equation 2) is applied to calculate the drug inhibition effect by finding the ratio of resulted active and inactive complexes, where Z represents the total number of subunits (the stoichiometry) in one biocomplex and M represents the number of drugged subunits in one biocomplex.
For example, if Z is 3, the probability of all combinations of drugged subunits (M) and undrugged subunits (N; M + N = Z) in a given biocomplex entity can be determined by the expansion of equation 2:
. That is, the probability of a complex element possessing three copies of drugged subunits in the population is , two copies of drugged and one copy of undrugged or wild-type subunit is , one copy of drugged and two copies of undrugged subunits is , and three copies of undrugged subunits is . Assuming there were 70% (p=0.7) of subunits inactivated by bound drugs, and 30% (q=0.3) unaffected subunits in the population, then the percentage of elements possessing at least two copies of normal subunits would be the sum of those possessing one copy of drugged and two copies of undrugged wild-type subunits, , and those possessing three copies of native subunits is . That is 3pq 2
In another example, if one complex contains 6 subunits, and 5 out of the 6 subunits need to remain uninhibited in order to be biologically functional, the active complex ratio in the population will be the sum of: 1) the probability of each element containing 5 undrugged subunits, and 2) the probability of each element containing 6 undrugged subunits.
The probability X in the population displaying a certain combination of undrugged versus drugged subunits can be predicted by a binomial distribution, as shown in equation 2. Table 2 shows the probability of a given element with M drugged and N undrugged subunits at increasing percentages of drugged subunits in the population, considering that the total subunits in one element (Z) is 3 or 12. The formula, (from equation 2) was used to calculate each combination probability value, the coefficient
this equation can also be calculated using Yang Hui Triangle, which is also called Pascal's Triangle, or binomial distribution (Fig. 1B) [79] .
In vitro virus assembly system used for testing the hypothesis
The highly sensitive in vitro phi29 assembly system was used to determine the inhibition efficiency of drugs targeting multi-subunit complexes [56, 66, 76, 80] . Bacteriophage phi29 DNA packaging motor contains one copy of genomic dsDNA, 6 copies of packaging RNA, 6 copies of ATPase protein gp16 and more than 10000 copies of ATP. The stoichiometry of RNA in phi29 has been proven by extensive studies including single-molecule studies [81] AFM images ( Fig.1D) [82, 83] , pRNA crystal structure determination (Fig.1E) [84] , and mathematical studies [56] . The stoichiometry of gp16 in phi29 has been proven by multiple approaches including native gel binding, capillary electrophoresis assays, Hill constant determination, and by titration of mutant subunits using binomial distribution [19, 33] . Many other AAA+ superfamily members have been found to be hexamers as well [85, 86, 87, 88, 89, 90, 91] , such as a red type rubisco activase AAA+ protein CbbX (Fig. 1F) [85] , MecA-ClpC molecular machine (Fig. 1G) [86] . The copy number of ATP molecules was calculated based on the fact that 6 ATP molecules are required to package one pitch of dsDNA with 10.5 basepairs (bp) [92] , thus 1 ATP is used to package 1.7 bp. The entire phi29 genome is composed of 19.4 kbp, thus, it is expected that more than 10000 ATP molecules are required to package the entire phi29 genome. The phi29 DNA nanomotor which packages an entire genomic DNA into the procapsid can be treated as a disease model for drug inhibition efficiency analysis.
In vitro testing of the hypothesis using DNA element with stoichiometry of 1 Table 2 . Probability of the complex containing M copies of drugged subunits and N copies of undrugged subunits The inhibition efficiency of drugs targeting a single subunit substrate was tested by in vitro phi29 assembly inhibition by mutating the genomic dsDNA ( Fig. 2A ). Various ratios of mutant DNA were mixed with wild-type DNA in in vitro viral assembly assays. The empirical curve of viral assembly efficiency against drugged mutant DNA ratio fits well with the theoretical curve from binomial distribution for Z = 1 and K = 1 (Fig. 2B ). This suggests that when designing drug targeting the genomic DNA in phi29 nanomotor, it is expected to be a first order inhibition response. Comparing the in vitro phi29 assembly inhibition, by adding drugged mutant DNA, with simply diluting wildtype DNA concentration as a control, revealed that the drugged mutant DNA didn't cause much difference (Fig. 2C) . The results showed that the inhibition effect of drugs targeting the substrate with stoichiometry of 1 is minimal.
In vitro testing of the hypothesis using RNA elements with stoichiometry of 6
The pRNA of phi29 contains two domains; a head-loop domain essential for procapsid binding and a helix domain essential for DNA translocation (Fig. 3A , upper panel) [30, 93, 94] . The right-hand loop and left-hand loop of two pairing pRNA molecules can interact with each other by complementary base pairing. Extensive studies have led to the conclusion that 6 copies of pRNA form a hexameric ring which binds to the procapsid for virus activity [81, 82, 83, 84] . Drugged mutant pRNA was constructed by mutating 4 nucleotide sequences at the 5'end region of pRNA (Fig. 3A, lower panel) , which has been shown to compete with wild-type pRNA for procapsid binding, but was found to be deficient in allowing DNA packaging to occur [67] . The theoretical curves generated using the expansion of binomial distribution equation while total subunit number Z is 6 and varying K number from 1 to 6 are shown in Fig. 3B . Fitting the empirical data from phage assembly efficiency at different ratios of drugged mutant pRNAs into the theoretical curves, the empirical data fit into the theoretical curve of Z = 6 and K = 1. It suggested that the pRNA oligomer ring is composed of six copies of pRNA subunits and one subunit of the pRNA multimer blockage is sufficient to block the phage assembly activity. Comparing the empirical curve for viral assembly efficiency against different ratios of drugged mutant pRNAs with the wild-type pRNA concentration dilution control, addition of drugged mutant pRNA showed a much stronger inhibition effect (Fig.3C) .
To further prove the concept that drugs targeting biocomplex with high stoichiometry causes stronger inhibition effect, antisense oligonucleotides which can bind to pRNA molecules were designed as mock drugs in the viral assembly assay. The oligonucleotides P15, and P3 were designed to target the 5'-end and 3'-end regions on pRNA, respectively. It was confirmed that the antisense oligonucleotides can be hybridized to pRNA by gel shift assay (data not shown). When mixing the antisense oligonucleotides with wildtype pRNA for in vitro phi29 assembly assay, complete inhibition effects were shown by antisense oligonucleotides P15, and P3, but not with the non-targeting control oligonucleotide P8 [95] . By mixing the non-targeting oligo P8 with pRNA, it generated plaques with 4.4×10 6 PFU on the plate.
In vivo testing of the hypothesis using RNA elements with stoichiometry of 6
Formation of the hexameric ring of pRNA in the phi29 dsDNA packaging motor has been discovered through biochemical and structural studies [52, 81, 84, 96, 97, 98, 99, 100, 101, 102, 103] and activity assays [94, 104] . The observed high inhibition efficiency by drugged mutant pRNA on phi29 assembly in vitro was striking [67, 105] . To test whether such a high level of inhibition was attainable in vivo, pRBmutRNA plasmid expressing a pRNA with 4base mutation at the 3' end ( Fig. 4A ) was transformed into B. subtilis DE1 cells. Plasmid pRBwtRNA contained the pRNA coding sequence but do not express pRNA in B. subtilis DE1 cells, and vector pRB381-L550 was introduced as well as a negative control. The results showed that only cells harboring pRBmutRNA plasmid were completely resistant to plaque formation by wild-type phi29 virus infection. Control cells, including B. subtilis 12A cells alone, B. subtilis DE1 cells carrying vector pRB381-L550 alone, and cells carrying a wild-type pRNA coding sequence but no expression plasmid pRBwtRNA were all positive for plaque formation (Fig. 4B) . The ability of mutant pRNAs generated in cells by plasmid pRBmutRNA completely inhibited plaque formation indicated that hexameric pRNA in DNA packaging nano-motor may be a potential target for developing potent antiviral agents [67] .
In vitro testing of the hypothesis using the ATPase with stoichiometry of 6
Hexameric folding of ATPase gp16 protein in the phi29 dsDNA packaging motor has been discovered [1, 19, 33, 35] . The hexameric gp16 protein complex functions as ATPase like many other AAA+ superfamily members. ATP binding to one subunit of gp16 stimulates the ATPase to change its conformation from having a lower affinity to one having a higher affinity for dsDNA.
Determination of gp16 stoichiometry was carried out by in vitro phage assembly assay and based on the binomial distribution of wild-type and Walker B mutant gp16 [51] . Different ratios of drugged Walker B mutant gp16 were mixed with undrugged gp16 to test the inhibition efficiency of gp16 mutation on phi29 DNA packaging motor. Assuming K equals 1 and the total copy number of gp16 (Z) is between 1 and 12, twelve theoretical curves for the production of phi29 virion against the ratio of the Walker B mutant corresponding to the stoichiometry (Z) of 1 to 12 were generated according to equation 2. The empirical data nearly perfectly overlapped the theoretical curve of Z=6, K=1 [51] . This data suggested that the ATPase gp16 components of phi29 DNA packaging motor have a stoichiometry of six, and only one copy of the drugged gp16 can block the phi29 motor function. Comparing the inhibition effect of adding mutant gp16 with wild-type gp16 at different concentrations, it showed that adding mutant gp16 had a much stronger inhibition effect than the wild-type gp16 concentration dilution control (Fig. 5A ).
Comparing the inhibition effect of mutation on hexameric gp16 to the effect of mutation on single subunit target DNA, the gp16 mutation displayed a much stronger inhibition effect on virus assembly than the same ratio of DNA mutation, indicating the hexameric ATPase protein complex of virus assembly system should also be an efficient target for generating new anti-virus drugs with high potency.
In vitro testing of the hypothesis using ATP with stoichiometry of more than 10000
It has been reported that 6 ATP molecules are required to package one pitch of dsDNA with 10.5bp [90] , thus 1 ATP is used to package 1.7bp. As the entire phi29 genomic DNA has 19,000 base pairs, it is expected that more than 10000 ATP molecules are required to package the entire phi29 genome. Since concerning ATP, the functional unit displayed in Fig 5 is the viral production expressed as plaque-forming unit (PFU), so the production of one functional unit of PFU require 10000 ATP subunits to package one genomic DNA. Thus, the ATP in one phi29 nanomotor can be regarded as a stoichiometry of 10000. One non-hydrolysable ATP analogue γ-S-ATP was treated as the drugged subunit that mixed with ATP at different ratios to test the inhibition effect of γ-S-ATP on phi29 assembly efficiency. It was found that the inhibition curve of mutant ATP fits into the theoretical curve between Z=100, K=1 and Z=60, K=1 (Fig. 5B) . The empirical ATP value derived from binomial distribution assay was different from real condition, since the binomial distribution equation was based on a condition that each subunits has the same binding affinity to the biocomplex in the targeted nanomotor, but due to the change of the γ-S-ATP structure, it has a ATPase gp16 binding affinity lower than the normal ATP . Furthermore, the affinity difference in each subunit has a multiplicative effect in the nanomotor's activity. Thus, there is a big discrepancy between the curves with predicted Z value and the empirical Z value.
Comparing virus assembly inhibition effect using different components, the γ-S-ATP showed a severe inhibition effect (Fig.  5C ). Adding 20% of gamma-s-ATP nearly completely inhibited the viral assembly. Comparing the inhibition effect targeting to ATP, pRNA, ATPase gp16, and DNA with stoichiometry of 10000, 6, 6, and 1, respectively, γ-S-ATP showed the strongest inhibition effect, while drugged mutant pRNA and mutant gp16 showed stronger inhibitory effect than mutant DNA (Fig.5C ). For example, adding 20% mutant DNA caused 20% inhibition effect in viral assembly, while 20% of drugged mutant pRNA exerted 74%of inhibition effect on viral assembly and 20% of γ-S-ATP almost completely inhibited the viral assembly, indicating the higher the stoichiometry, the stronger the inhibition efficacy.
Mathematical reasoning for the increase of inhibition efficacy
Using a biological complex with higher stoichiometry as drug target will substantially reduce the proportion of non-inhibited complex. For K=1, the proportion of non-inhibited complex is q Z . Table 3 compares the proportion of non-inhibited complex from two populations with Z=6 and Z=1, respectively, with varied substrate targeting efficiency (p) when K =1. For example, when q=0.4, the proportion of non-inhibited complex is q Z =0.4 1 =0.4 for Z=1, K=1. Therefore, only 1-0.4=60% of complex is inhibited. In contrast, for Z=6, K=1, the proportion of non-inhibited complex is q Z =0.4 6 =0.0041. Therefore, 1-0.0041=99.59% of complex is inhibited. The ratio of the proportions of non-inhibited complex equals 0.0041/0.4 = 0.0102, indicating a 1/0.0102=98-fold decrease in the proportion of noninhibited complex. One more example is to use the drug targeting efficiency p = 0.9 to compare the inhibition efficiency between two groups with Z=6 and Z=1. For Z=6, K=1, the proportion of inhibited complex is 1-q Z =1-0. indicating a 10000-fold increase in inhibition efficiency ( Table 3 ).
The equation displays inhibitory effect with a power function of stoichiometry since when K=1, the percentage of uninhibited biocomplexes in the population equal to q z . Since (P + q) = 1, thus q ≤ 1, thus the larger the Z, the smaller the value of q z That is to say, the higher the stoichiometry, the smaller number of the uninhibited background will display. With the same substrate targeting efficacy, p, the inhibition efficiency is determined by z, the power of the equation component. The inhibitory effect is a power function concerning the stoichiometry. Thu, the higher the stoichiometry, the more efficient the inhibition comparing the drugs with same binding affinity.
The half maximal inhibitory concentration (IC 50 ) is commonly used to evaluate drug effect, which quantitatively indicates how much of a particular drug is needed to inhibit a given biological process by half.
If we denote as the percentage of drugged subunit needed to reach to 50% inhibition in the in vitro assay in the defined system, thus .Solving this equation,
. Figure 6 shows the relationship between stoichiometry (Z) and drug targeting level p to reach the inhibition . 6) , and hence the drug is more potent.
Discussion
Aiming to find a method for developing drugs with ultra-high potency, we proposed that the inhibition efficiency of a given drug depends on stoichiometry of the biocomplex or bio-machine that was used as drug target. Here the definition of the stoichiometry is different from conventional definition of stoichiometry used to evaluate drug efficiency. Conventional thinking in drug development emphasizes stoichiometry which refers to the number of drug binding per target molecule, which is also known as B max . In this study the definition of stoichiometry refers to the copy number of subunit within a biocomplex that serves as drug target. We used phi29 viral components with a series of variable but known stoichiometry as mock drug targets to test the hypothesis. Both in vitro and in vivo virion assembly assays were employed to compare the inhibition efficiency targeting to components with different numbers of subunit stoichiometry. Viral inhibition efficiency was analyzed with Yang Hui's (Pascal's) Triangle (or knowns as binomial distribution). It was found that inhibition efficiency on virus replication correlates to the component stoichiometry of nano-machine as drug target. It displayed power law inhibitory effect since when K=1, the percentage of uninhibited biocomplexes in the population equal to q z . With the same q and same K value, the inhibition efficiency is determined by z, the number of subunits within the biocomplex or the bio-machine as drug target. Here z serves as the power in the equation, thus, the inhibitory effect is the power of the stoichiometry. Empirical data demonstrated that the target with thousand-subunits shows higher inhibition effect than the targets with six subunits, and in turn higher than the target with single subunit.
In evaluation of drug effect, two parameters were commonly used. One is the half maximal inhibitory concentration (IC 50 ), which quantitatively indicates how much of a particular drug is needed to inhibit a given biological process by half. It is universally used as a measure of drug potency in pharmacological research. Another important parameter is the median lethal dose (LD 50 ), which is also known as 50% of lethal concentration (LC 50 ). LD 50 is frequently used to indicate a substance's acute toxicity. Obviously, the usefulness of a drug will dependent on the ratio of LD 50 to IC 50. The larger this ratio, the safer the drug. By ways of increasing the inhibition efficiency through targeting to the components with high stoichiometry, the IC 50 of a drug will decrease. As a result, lower concentration of drug will be required for reaching a desired effect, resulting in a reduced toxicity of the drug.
Most of current anti-cancer, anti-virus or anti-bacteria drugs target single enzymes or single proteins. Our data showed that drugs selected to target components, biocomplexes, or nano-machines with high copy numbers could lead to a much higher efficacy, and it could potentially solve the problem of low drug effect and multi-drug resistance.
Conclusions
Targeting the functional biological units with higher stoichiometries will have a higher efficiency of inhibition. The inhibition effect is power, other than proportional, and the power, is the copy number of the drug-targeted element of the machine. The new theory developed herein suggests that potent drugs can be developed by targeting biocomplex with high stoichiometry, and a complete inhibition of virus, bacterium, or cancer is possible if a bio-machine with high stoichiometry is identified. Since bio-motors share certain common structure and operation mechanism in viruses, bacteria, and cells, this approach should have general application in drug development.
Future Perspective
Living systems contain many elegant arrays, motors and nanomachines that are multi-subunit complex. As reported here, these biocomplex with high copy number of components can serve as potent drug targets. For example, most members of the AAA+ family are hexamer [19, 87, 88, 106, 107, 108] . However, these machines are common in living systems therefore the specificity and toxicity is an issue. For bacteria and virus, since our goal is to kill them nonexclusively, the specificity and toxicity is not an issue as long as the target biocomplex is not identical to that in human body. For cancers drugs, as long as a mutation is found in the multiplesubunit biocomplex, it will be an ideal target for potent drug.
Executive summary Aim
• A method for developing potent drugs is sought.
Hypothesis
• Drug inhibition potency depends on the stoichiometry of the targeted biocomplex.
Approach: Nanomedicine(Lond.) (2015) 10 (12), 1881-1897 ISSN 1743-5889
• Phi29 viral components with variable stoichiometry were used as model to prove the hypothesis • Virion assembly efficiency was assayed and analyzed with Yang Hui's Triangle:
Results:
• Inhibition efficiency displayed a power function of the stoichiometry of the target biocomplexes. The uninhibited biocomplex in population can equals to q z . Thus, the inhibitory effect is a power of the stoichiometry.
• Targets with thousand-subunit showed higher inhibition effect than with six subunits, and in turn higher than target with single subunit.
• A complete inhibition of virus, bacterium, or cancer was demonstrated when targets with high stoichiometry was used as target.
Conclusion
• Drug inhibition potency depends on the stoichiometry of the targeted components of the biocomplex or nano-machine.
• The inhibition effiect displayed a power funciton of the stoichiometry of the target biocomplex.
• Since bio-motors share certain common structure and operation mechanism in viruses, bacteria, and cells, this approach should have general application in drug development.
